AR 2015

R&D Update 2016

NY, June 15
'Our aim is to evolve to a stable portfolio, delivering three clinical Proofs-of-Concept per year and to initiate one Phase 3 program every two years' 

Replay the webcastDownload the presentation

Welcome to Galapagos

Galapagos seeks to develop a robust portfolio of clinical-stage breakthrough therapies that have the potential to revolutionize existing treatment paradigms. Our ambition is to become a leading global biotechnological company, focused on the development and commercialization of novel medicines that will improve people’s lives.

Learn more about Galapagos

Novel targets, better treatments

Watch our target discovery animation. 

Read more


Global development filgotinib

Galapagos and Gilead have announced a global partnership to develop and commercialize filgotinib for the treatment of rheumatoid arthritis and other inflammatory diseases.

Read more